Indian Journal of Surgical Oncology最新文献

{"title":"AI-Enhanced 4D CT Radiotherapy Planning for Personalized Lung Cancer Treatment with Respiratory Motion Management.","authors":"Mariem Trabelsi, Lotfi Ben Salem, Hamida Romdhane, Dorra Ben-Sellem","doi":"10.1007/s13193-025-02322-8","DOIUrl":"https://doi.org/10.1007/s13193-025-02322-8","url":null,"abstract":"<p><p>Lung cancer radiotherapy is a complex treatment modality, heavily influenced by tumor motion and the shifting positions of organs at risk (OARs) during the respiratory cycle. This study proposes a personalized radiotherapy planning approach that incorporates respiratory dynamics by utilizing 4D CT imaging. The method integrates advanced segmentation techniques, motion tracking, and optical flow algorithms to track tumor displacement and the relative positions of OARs throughout different respiratory phases. Initially, segmentation is performed using a modified ResNet-50 architecture, tailored to delineate the lungs, tumors, and critical structures accurately. This architecture is enhanced by replacing the last layers with specialized ones to improve resolution and boundary delineation. To address the dynamic nature of respiratory motion, motion tracking algorithms are used to monitor and predict tumor displacement in real time. Additionally, optical flow techniques are employed to assess and compensate for inter-phase motion. For each respiratory phase, segmented slices are reconstructed in 3D using the marching cube algorithm, providing a detailed, continuous representation of the anatomical structures involved. The optimal respiratory phase for treatment is determined by analyzing tumor and OAR movement, ensuring minimal radiation exposure to healthy tissues while maximizing tumor irradiation. This approach has objectified that the choice of the ideal phase varies from one patient to another, depending on tumor size, location, and the proximity of organs at risk. The system is designed to automatically identify this optimal phase, enhancing the accuracy and effectiveness of radiotherapy and leading to improved patient outcomes.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"281-294"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemithyroidectomy: a Safe Bet for Papillary Carcinoma?-a Propensity Score Matching Observational Study with a 10-Year Follow-Up from a Tertiary Care Center in Northern India.","authors":"Azher Mushtaq, Aaqib Akbar Wani, Mohd Fazl Ul Haq, Ajaz Ahmad Malik, Munir Ahmad Wani, Zubair Gul Lone","doi":"10.1007/s13193-025-02319-3","DOIUrl":"https://doi.org/10.1007/s13193-025-02319-3","url":null,"abstract":"<p><p>The rising incidence of differentiated thyroid cancer (DTC), particularly papillary thyroid carcinoma (PTC), has sparked interest in de-escalating surgical management to reduce morbidity while maintaining oncological safety. While total thyroidectomy remains the standard of care, hemithyroidectomy has emerged as a potential alternative for low- to moderate-risk PTC. This study evaluates the feasibility and oncological outcomes of hemithyroidectomy compared to total thyroidectomy in a tertiary care center in Northern India. This observational study included 214 patients diagnosed with PTC between 2010 and 2015. Patients were divided into two groups: 107 underwent hemithyroidectomy, and 107 underwent total thyroidectomy. The groups were matched for age, gender, tumor size, and ATA risk stratification. Primary outcomes included disease-free survival (DFS), structural recurrence, and all-cause mortality over 1, 5, and 10 years. Statistical analysis was performed to compare outcomes between the two groups. The mean age at diagnosis was 41.72 ± 5.2 years in the hemithyroidectomy group and 40.6 ± 5.2 years in the total thyroidectomy group (<i>p</i> = 0.47). Tumor size (1.67 ± 0.37cm vs. 1.78 ± 0.30, <i>p</i> = 0.073) and ATA risk stratification (low risk: 65 vs. 61, <i>p</i> = 0.57; intermediate risk: 42 vs. 46, <i>p</i> = 0.57) were comparable. Structural recurrence rates at 1, 5, and 10 years were similar between groups with no statistically significant difference (<i>p</i> = 0.166). The 5-year DFS rates were 95.00% (hemithyroidectomy) and 97.10% (total thyroidectomy), while the 10-year DFS rates were 93.45% and 96.26%, respectively. Hemithyroidectomy demonstrates comparable oncological safety to total thyroidectomy in low- to selected moderate-risk PTC, which include patients with microscopic extra thyroidal extension and microscopic capsular & vascular invasion, supporting its role as a conservative surgical option. Strict adherence to follow-up protocols is essential to detect and manage recurrence promptly. Careful patient selection and individualized treatment planning are critical to achieving optimal outcomes in the era of surgical de-escalation for thyroid cancer.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"340-344"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of the BI-RADS, Using Both Mammograms and Sonograms, in Distinguishing Between Benign and Malignant Breast Masses.","authors":"Neha Nupur, Madhusmita Mohanty, Katyayani Panda, Nihar Ranjan Mohanty, Sashibhusan Dash","doi":"10.1007/s13193-025-02432-3","DOIUrl":"https://doi.org/10.1007/s13193-025-02432-3","url":null,"abstract":"<p><p>The American College of Radiology (ACR) created the Breast Imaging Reporting and Data System, or BI-RADS, to standardize the way radiologists report mammography, ultrasound, and MRI findings. This study aimed to compare the diagnostic accuracy of combined mammography and sonography with that of mammography alone in differentiating malignant from benign breast masses. This 3-year, hospital-based cross-sectional study included female patients presenting with breast lumps. Diagnostic accuracy metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy, were calculated with histopathology as the gold standard. This study evaluated 590 female patients with breast lumps (mean age 46.3 years), identifying 330 benign and 260 malignant cases. Fibroadenoma and invasive ductal carcinoma were the most common diagnoses. Patient age and body mass index (BMI) were significantly correlated with diagnosis, with an increased incidence of malignancy in the older and higher BMI groups, unlike fertility status; and, crucially, combining mammography with ultrasonography significantly enhanced breast lesion detection. This combined approach increased the sensitivity from 94.62% to 99.23% and the specificity from 86.67% to 90.91%. Consequently, both the PPV (84.83% to 89.58%) and NPV (95.33% to 99.34%) improved, resulting in an overall increase in diagnostic accuracy from 90.17% to 94.58%. This study revealed that combining mammography and sonography significantly improves the diagnostic accuracy for palpable breast masses, especially in differentiating between benign and malignant lesions. Integrating both imaging techniques into standard practice will lead to early diagnosis of malignant lesions and help avoid unnecessary biopsies for benign lesions.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13193-025-02432-3.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"462-468"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Interim Results from a Randomized Trial.","authors":"Ravi Shankar Biswas, Sulagna Das, Dipankar Ray, Shaunli Konar, Dilip Kumar, Md Basir Ahmed","doi":"10.1007/s13193-025-02337-1","DOIUrl":"https://doi.org/10.1007/s13193-025-02337-1","url":null,"abstract":"<p><p>Locally advanced rectal cancer (LARC) poses a significant treatment challenge, as conventional chemo-radiotherapy (CRT) frequently results in poor rates of pathological complete response (pCR) and distant metastasis. Total neoadjuvant chemotherapy followed by surgery may have the potential to improve overall outcomes and are coming onto clinical practice. This study aims to compare the efficacy and safety of TNT (Arm A) versus conventional CRT (Arm-B) in achieving pCR and distant metastasis in both the arms. It is an open-labelled randomized controlled trial. Total 172 patients were enrolled in the trial having histologically confirmed LARC (stages T3-T4 or any T stage with lymph node involvement) from June 2021 to June 2023. Patients were randomized to either Arm-A (<i>n</i> = 87) or Arm-B (<i>n</i> = 85). This interim analysis was conducted after two-thirds of the target sample had completed 1-year follow-up. The patients in the Arm A received preoperative radiotherapy with concurrent capecitabine followed by three cycles of capecitabine plus oxaliplatin (CapOx) while those on Arm B received radiotherapy with concurrent capecitabine only followed by 6 cycles of adjuvant CapOx. The primary objective was pCR, being no residual tumor cells (ypT0N0) in the resection specimen. Secondary endpoints were tumor regression score (TRG), circumferential resection margin (CRM) positivity, radicality of the resection margin, local recurrence and distant metastasis, and safety profile. In the interim analysis, which included 150 patients with 75 in each group, pCR was observed in 16.2% of Arm A and 17.4% of Arm-B (<i>p</i> > 0.05). There was no difference in tumor regression scores between the groups. Nonetheless, the TNT group significantly suffered less with distant metastasis at 1 year (6 vs.16 cases; <i>p</i> = 0.040). Local recurrence, CRM positive, or resection margin status did not show any relative difference. There were no significant adverse effects reported in both groups, and toxicity was moderate. This interim analysis suggests that while pCR is comparable in both the groups, TNT may offer superior systemic control by reducing distant metastasis. The findings also suggests the potential of TNT as a preferred treatment strategy in patients with LARC, though completion of the study and a long term follow-up is required to confirm its benefits. Clinical Trials Registry of India: CTRI/2021/05/033642.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"387-397"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgeon-a Scalpel Holder<i>:</i> Trusted and Inseparable Friend.","authors":"Satish K Shukla, Sumit Shukla","doi":"10.1007/s13193-025-02302-y","DOIUrl":"https://doi.org/10.1007/s13193-025-02302-y","url":null,"abstract":"<p><p>This article focuses on a simple but crucial instrument used in every surgical procedure: the Scalpel. The first step of any surgery is making an incision on the operative site, which opens the way for the surgeon to explore tissue spaces, identify structures, and proceed with the operation. For centuries, surgeons around the world have operated based on the medical systems of their time, aided by available instruments, equipment, and trained paramedical staff-all united in their shared commitment to alleviating human suffering. The history of medicine spans over 3,000 years, from prehistoric times through the Babylonian era, the Arabic period, the Enlightenment, and into the Modern Digital Age. Despite many advancements, the Scalpel remains the First instrument that a surgeon reaches for, to begin an operation. This article delves into the history, significance, and role of the Scalpel, observing how it has withstood the test of time and continues to be indispensable despite the rise of high-tech surgical procedure. Observation is the key to identify the relationship of Surgeon and Scalpel, an inseparable one.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"258-261"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between miR-539 and miR-6824 and Their Target Gene, <i>MAP2K1</i>, Expression Level in Oral Cancer.","authors":"Sara Bagheri Farahani, Farzaneh Jahangiri, Faranak Jamshidian, Hadise Mohammadpour","doi":"10.1007/s13193-025-02292-x","DOIUrl":"https://doi.org/10.1007/s13193-025-02292-x","url":null,"abstract":"<p><p>Oral cancer affects millions of people with a high mortality rate throughout the world. Increasing evidences have demonstrated that mircoRNAs (miRNAs) play crucial roles in the modulation of tumour growth and progression, whereas the functional role of miR-539 and miR-6824 in oral cancer is not well established. The mitogen-activated protein kinase (MAPK) pathway has a master control role in various cancer-related biological processes as cell growth, proliferation, differentiation, migration, and apoptosis. Mitogen-activated protein kinase 1, also known as <i>MAP2K1</i>, was verified as the target of miR-539 and miR-6824. In our present study, we sought to explore biological role of miR-539 and miR-6824 in OSCC progression and for better specificity and efficiency; stem-loop primers followed by real-time polymerase chain reaction have been determined. The expression level of miR-539 and miR-6824 expression was downregulated in OSCC tissues (<i>p</i> value = 0.00) (<i>p</i> value = 0.269) and OLP tissues (<i>p</i> value = 0.006) (<i>p</i> value = 0.054). Significant upregulation of <i>MAP2K1</i> gene was noted in the OLP (<i>p</i> value = 0.034) and OSCC (<i>p</i> value = 0.01), specimens compared with healthy controls. Significant positive correlations were observed between miR-539 and miR-6824 (<i>p</i> value = 0.05). Receiver operating characteristic (ROC) curve analysis was performed to assess the sensitivity and specificity of miRNAs as diagnostic biomarkers and result showed area under the ROC curve (AUC) of <i>map2k1</i> was 0.92, has_miR_539 the area under ROC curve (AUC) was of 0.982 (<i>p</i> = 0.0001) and has_miR_6824 was 1.000 (<i>p</i> < 0.0001). This study provides the first evidence of the miR-539 and miR-6824 role in oral cancer and suggests a potential therapeutic target and prognostic predictor for oral cancer.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"262-273"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative Frozen Section Analysis for Margin Status in Breast Conserving Therapy: a Retrospective 6-Year Experience at a Tertiary Centre in North East India.","authors":"Dibyajyoti Deka, Clara Atieno Odhiambo, Abhijit Talukdar, B B Borthakur, Pompi Daimari Buragohain, Deep Jyoti Kalita, Gaurav Das, Shivaji Sharma","doi":"10.1007/s13193-025-02301-z","DOIUrl":"https://doi.org/10.1007/s13193-025-02301-z","url":null,"abstract":"<p><p>Breast cancer is the commonest cancer among Indian women as it is globally. Margin status post lumpectomy remains an important predictor of local recurrence after breast conserving surgery. We set out to investigate the positive predictive value of intra operative frozen section analysis in a tertiary cancer center in North East India. Retrospective data from all women who underwent breast conserving Surgery (BCS) from 2017 to 2022 was included. Frozen section analysis reports were compared against final pathology reports. Comparison was in regard to margin status. Two hundred ten women underwent BCT, and mean age was 49.5 years. The sensitivity and specificity of frozen section was 92.5% (86.2-95.64% 95% CI) and 99.8% (62.23-99.9% 95% CI) respectively. The PPV and NPV was 94.8% (87.09-99.86% 95% CI) and 99.8% (95.53-99.9% 95 CI). Our analysis showed an accuracy of 99.63% (95.22-99.96%, 95% CI). We concluded that frozen section analysis is accurate and has a high positive predictive value and negative predictive value for margin status in breast conserving surgery.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"295-301"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mandatory Pan-India Cancer Notification: from Policy Gap to National Priority.","authors":"Pankaj Kumar Garg, Pallvi Kaul","doi":"10.1007/s13193-026-02530-w","DOIUrl":"https://doi.org/10.1007/s13193-026-02530-w","url":null,"abstract":"","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"255-257"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal Neuroendocrine Tumours: A 10-Year Review of Clinical Presentation, Pathological Features, and Treatment Outcomes from a Tertiary Care Cancer Centre in Western India.","authors":"Katyayani Kumari, Vivekanand Sharma, Ashwin DeSouza, Mufaddal Kazi, Ankit Sharma, Vikram Anil Chaudhari, Munita Bal, Avanish Saklani","doi":"10.1007/s13193-025-02323-7","DOIUrl":"https://doi.org/10.1007/s13193-025-02323-7","url":null,"abstract":"<p><p>Rectal neuroendocrine tumours are rare but increasing worldwide. However, there is limited data from regions like the Indian subcontinent, where clinical presentations and outcomes may differ due to unique demographic and biological factors. This study aimed to characterize rectal neuroendocrine tumours in our region, focusing on clinic-pathological presentation, and treatment outcomes. This was an observational single-centre retrospective cohort study from a high-volume tertiary care centre in Western India. Sixty-five consecutive patients with rectal neuroendocrine tumours treated between 2013 and 2023 were included. The main outcome measures were overall survival and disease-free survival. Secondarily, we tried to evaluate the impact of pathological grade and surgery-type on survival outcomes. The median age at diagnosis was 50 years, younger than the global median (56-57 years), with a male predominance (80%). Majority of patients were symptomatic and had locally advanced disease, with 64% showing metastatic spread. Pathologically, 82% of tumours were classified as Grade II/III, with a high median tumour size (3.7 cm) and elevated serum Chromogranin A levels. Multimodal treatment, including surgery and adjuvant therapies, was utilized for most patients. Of the 41.5% who underwent surgery, 70% had sphincter-preserving procedures. The median overall survival for the entire cohort was not reached, but 3-year and 5-year overall survival rates were 91% and 85%, respectively. Grade III tumours had significantly poorer outcomes, with a 5-year survival of 57% compared to nearly 100% in Grade I and II tumours. Apart from its retrospective nature, our study may have limited generalizability due to potential referral bias, and the lack of detailed pathological subclassification would be an opportunity for future research. As the first study from the Indian subcontinent we highlight how our patients presented at a younger age with advanced, aggressive disease. Multimodal approach could improve outcomes even in advanced disease.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"368-378"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience-Based Procedure Card for Robot-Assisted Nipple Sparing Mastectomy Using the SSI Mantra, Indian Robotic Surgical System.","authors":"Somashekhar Sp, Medha Sugara, Ashwin Kr, Rohit Kumar, Kushal Agrawal, Srikarthik Voleti, Anagha Zope","doi":"10.1007/s13193-025-02326-4","DOIUrl":"https://doi.org/10.1007/s13193-025-02326-4","url":null,"abstract":"<p><p>The SSI MANTRA™ (Sudhir Srivastava Innovations Pvt. Ltd, Haryana, India) robotic surgical system developed in India has been used to perform various complex procedures of the abdomen and thorax. The robot-assisted nipple sparing mastectomy (RANSM) described by Toesca et al. is different from these procedures because it utilizes a confined working space created in the soft tissue of the breast and has been described on the da Vinci Intuitive Surgical System. We performed the procedure of RANSM in a woman with early breast cancer using the SSI MANTRA™ and found it feasible. Case selection, docking, and surgical technique are described here.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 2","pages":"351-355"},"PeriodicalIF":0.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}